Literature DB >> 31591735

Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma.

Abdullah S Al Saleh1,2, M Hasib Sidiqi1, Morie A Gertz1, Eli Muchtar1, Martha Q Lacy1, Rahma M Warsame1, Wilson I Gonsalves1, Taxiarchis V Kourelis1, William J Hogan1, Suzanne R Hayman1, Prashant Kapoor1, Francis K Buadi1, Angela Dispenzieri1, David Dingli1, Shaji K Kumar1.   

Abstract

Entities:  

Keywords:  autologous stem cell transplant; daratumumab; delayed neutrophil engraftment; multiple myeloma

Mesh：

Substances：

Year:  2019        PMID： 31591735      PMCID： PMC7388699          DOI： 10.1002/ajh.25654

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Authors:  Philippe Moreau; Michel Attal; Cyrille Hulin; Bertrand Arnulf; Karim Belhadj; Lotfi Benboubker; Marie C Béné; Annemiek Broijl; Hélène Caillon; Denis Caillot; Jill Corre; Michel Delforge; Thomas Dejoie; Chantal Doyen; Thierry Facon; Cécile Sonntag; Jean Fontan; Laurent Garderet; Kon-Siong Jie; Lionel Karlin; Frédérique Kuhnowski; Jérôme Lambert; Xavier Leleu; Pascal Lenain; Margaret Macro; Claire Mathiot; Frédérique Orsini-Piocelle; Aurore Perrot; Anne-Marie Stoppa; Niels Wcj van de Donk; Soraya Wuilleme; Sonja Zweegman; Brigitte Kolb; Cyrille Touzeau; Murielle Roussel; Mourad Tiab; Jean-Pierre Marolleau; Nathalie Meuleman; Marie-Christiane Vekemans; Matthijs Westerman; Saskia K Klein; Mark-David Levin; Jean Paul Fermand; Martine Escoffre-Barbe; Jean-Richard Eveillard; Reda Garidi; Tahamtan Ahmadi; Sen Zhuang; Christopher Chiu; Lixia Pei; Carla de Boer; Elena Smith; William Deraedt; Tobias Kampfenkel; Jordan Schecter; Jessica Vermeulen; Hervé Avet-Loiseau; Pieter Sonneveld
Journal:  Lancet       Date:  2019-06-03       Impact factor: 79.321

2.  Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells.

Authors:  F Malavasi; F Caligaris-Cappio; C Milanese; P Dellabona; P Richiardi; A O Carbonara
Journal:  Hum Immunol       Date:  1984-01       Impact factor: 2.850

3.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

Review 4.  Human CD38: a glycoprotein in search of a function.

Authors:  F Malavasi; A Funaro; S Roggero; A Horenstein; L Calosso; K Mehta
Journal:  Immunol Today       Date:  1994-03

5.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors:  Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

6.  Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.

Authors:  Xu Steven Xu; Meletios A Dimopoulos; Pieter Sonneveld; P Joy Ho; Andrew Belch; Merav Leiba; Marcelo Capra; David Gomez; Eva Medvedova; Shinsuke Iida; Chang-Ki Min; Jordan Schecter; Richard Jansson; Liping Zhang; Yu-Nien Sun; Pamela L Clemens
Journal:  Adv Ther       Date:  2018-10-29       Impact factor: 3.845
  6 in total
  2 in total

1.  EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.

Authors:  Sotirios Michaleas; Elisabeth Penninga; Doris Hovgaard; Anne-Marie Dalseg; Aldana Rosso; Sinan B Sarac; Jorge Camarero Jimenez; Lucia López-Anglada Fernández; Carolina Prieto Fernández; Victor Mangas-SanJuan; Isabel Garcia; Concepcion Payares-Herrera; Aranzazu Sancho-López; Harald Enzmann; Marcia Sofia Sanches de Castro Lopes Silva; Sílvia Duarte; Francesco Pignatti
Journal:  Oncologist       Date:  2020-10-16

Review 2.  Daratumumab in untreated newly diagnosed multiple myeloma.

Authors:  Nadine Abdallah; Shaji K Kumar
Journal:  Ther Adv Hematol       Date:  2019-12-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.